Clinical Research Directory
Browse clinical research sites, groups, and studies.
Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis
Sponsor: Central Hospital, Nancy, France
Summary
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and represents the main cause of mortality. Disease course in SSc-ILD is highly variable: patients can experience stable disease, slow or fast progression. Prevention of ILD progression now represents a key objective of SSc-ILD management. The understanding of the course and patterns of SSc-ILD progression is necessary, as reliable prediction tools that allow the stratification of the risk of progression. We aimed to identify the longitudinal trajectories of ILD in SSc patients using latent class mixed models and to examine their associations with SSc characteristics.
Official title: Evaluation of Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis (SCLEROPIDEVOL Study)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
600
Start Date
2023-05-01
Completion Date
2025-09-01
Last Updated
2024-08-27
Healthy Volunteers
No
Locations (1)
CHU Nancy
Vandœuvre-lès-Nancy, Grand Est, France